000156721 001__ 156721
000156721 005__ 20240229133504.0
000156721 0247_ $$2doi$$a10.1038/s41397-020-0174-1
000156721 0247_ $$2pmid$$apmid:32546699
000156721 0247_ $$2ISSN$$a1470-269X
000156721 0247_ $$2ISSN$$a1473-1150
000156721 0247_ $$2altmetric$$aaltmetric:84105897
000156721 037__ $$aDKFZ-2020-01059
000156721 041__ $$aeng
000156721 082__ $$a610
000156721 1001_ $$00000-0003-3218-0539$$aGuberina, Maja$$b0
000156721 245__ $$aERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy.
000156721 260__ $$aBasingstoke$$bNature Publishing Group$$c2021
000156721 3367_ $$2DRIVER$$aarticle
000156721 3367_ $$2DataCite$$aOutput Types/Journal article
000156721 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1641905192_13364
000156721 3367_ $$2BibTeX$$aARTICLE
000156721 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000156721 3367_ $$00$$2EndNote$$aJournal Article
000156721 500__ $$a2021 Feb;21(1):37-46
000156721 520__ $$aIdentifying patients with locally advanced head and neck carcinoma on high risk of recurrence after definitive concurrent radiochemotherapy is of key importance for the selection for consolidation therapy and for individualized treatment intensification. In this multicenter study we analyzed recurrence-associated single-nucleotide polymorphisms (SNPs) in DNA repair genes in tumor DNA from 132 patients with locally advanced head and neck carcinoma (LadHnSCC). Patients were treated with definitive radiotherapy and simultaneous cisplatin-based chemotherapy at six partner sites of the German Cancer Consortium (DKTK) Radiation Oncology Group from 2005 to 2011. For validation, a group of 20 patients was available. Score selection method using proportional hazard analysis and leave-one-out cross-validation were performed to identify markers associated with outcome. The SNPs rs1799793 and rs13181 were associated with survival and the same SNPs and in addition rs17655 with freedom from loco-regional relapse (ffLRR) in the trainings datasets from all patients. The homozygote major rs1799793 genotype at the ERCC2 gene was associated with better (Hazard ratio (HR): 0.418 (0.234-0.744), p = 0.003) and the homozygote minor rs13181 genotype at ERCC2 with worse survival (HR: 2.074, 95% CI (1.177-3.658), p = 0.017) in comparison to the other genotypes. At the ffLRR endpoint, rs1799793 and rs13181 had comparable prognostic value. The rs1799793 and rs13181 genotypes passed the leave-one-out cross-validation procedure and associated with survival and ffLRR in patients with LadHnSCC treated with definitive radiochemotherapy. While findings were confirmed in a small validation dataset, further validation is underway within a prospective biomarker study of the DKTK.
000156721 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000156721 588__ $$aDataset connected to CrossRef, PubMed,
000156721 7001_ $$aSak, Ali$$b1
000156721 7001_ $$aPöttgen, Christoph$$b2
000156721 7001_ $$0P:(DE-HGF)0$$aTinhofer-Keilholz, Ingeborg$$b3
000156721 7001_ $$0P:(DE-HGF)0$$aBudach, Volker$$b4
000156721 7001_ $$aBalermpas, Panagiotis$$b5
000156721 7001_ $$0P:(DE-HGF)0$$aVon der Grün, Jens$$b6
000156721 7001_ $$0P:(DE-HGF)0$$aRödel, Claus Michael$$b7
000156721 7001_ $$aGikka, Eleni$$b8
000156721 7001_ $$0P:(DE-HGF)0$$aGrosu, Anca-Ligia$$b9
000156721 7001_ $$0P:(DE-He78)360c5bc2b71a849e35aca747c041dda7$$aAbdollahi, Amir$$b10$$udkfz
000156721 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b11$$udkfz
000156721 7001_ $$0P:(DE-HGF)0$$aBelka, Claus$$b12
000156721 7001_ $$0P:(DE-HGF)0$$aPigorsch, Steffi$$b13
000156721 7001_ $$0P:(DE-HGF)0$$aCombs, Stephanie$$b14
000156721 7001_ $$0P:(DE-He78)a71604d1adbf3bced939fcfcf2c7ff32$$aMönnich, David$$b15
000156721 7001_ $$0P:(DE-HGF)0$$aZips, Daniel$$b16
000156721 7001_ $$aDe-Colle, Chiara$$b17
000156721 7001_ $$aWelz, Stefan$$b18
000156721 7001_ $$0P:(DE-He78)81b719227985a27b1b77ed6766094319$$aLinge, Annett$$b19$$udkfz
000156721 7001_ $$0P:(DE-HGF)0$$aLohaus, Fabian$$b20
000156721 7001_ $$0P:(DE-HGF)0$$aBaretton, Gustavo$$b21
000156721 7001_ $$aGauler, Thomas$$b22
000156721 7001_ $$0P:(DE-He78)933f7d725ac87378f459623783585a1f$$aBaumann, Michael$$b23$$udkfz
000156721 7001_ $$0P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9$$aKrause, Mechthild$$b24$$udkfz
000156721 7001_ $$0P:(DE-HGF)0$$aSchuler, Martin$$b25
000156721 7001_ $$aBankfalvi, Agnes$$b26
000156721 7001_ $$aHöing, Benedikt$$b27
000156721 7001_ $$aLang, Stephan$$b28
000156721 7001_ $$aStuschke, Martin$$b29
000156721 773__ $$0PERI:(DE-600)2051501-7$$a10.1038/s41397-020-0174-1$$n1$$p37-46$$tThe pharmacogenomics journal$$v21$$x1473-1150$$y2021
000156721 909CO $$ooai:inrepo02.dkfz.de:156721$$pVDB
000156721 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000156721 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000156721 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000156721 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000156721 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000156721 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)360c5bc2b71a849e35aca747c041dda7$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000156721 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000156721 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000156721 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000156721 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000156721 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a71604d1adbf3bced939fcfcf2c7ff32$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000156721 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000156721 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)81b719227985a27b1b77ed6766094319$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000156721 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000156721 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000156721 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)933f7d725ac87378f459623783585a1f$$aDeutsches Krebsforschungszentrum$$b23$$kDKFZ
000156721 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9$$aDeutsches Krebsforschungszentrum$$b24$$kDKFZ
000156721 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b25$$kDKFZ
000156721 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000156721 9130_ $$0G:(DE-HGF)POF3-319H$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000156721 9141_ $$y2021
000156721 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPHARMACOGENOMICS J : 2018$$d2020-01-15
000156721 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-15
000156721 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-15
000156721 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-15
000156721 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-01-15
000156721 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-01-15
000156721 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-15
000156721 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-01-15
000156721 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-15
000156721 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-15
000156721 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-15
000156721 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-01-15
000156721 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-01-15
000156721 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-01-15
000156721 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-01-15
000156721 9201_ $$0I:(DE-He78)BE01-20160331$$kBE01$$lDKTK BE zentral$$x0
000156721 9201_ $$0I:(DE-He78)FR01-20160331$$kFR01$$lDKTK FR zentral$$x1
000156721 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000156721 9201_ $$0I:(DE-He78)FM01-20160331$$kFM01$$lDKTK FM zentral$$x3
000156721 9201_ $$0I:(DE-He78)E210-20160331$$kE210$$lE210 Translationale Radioonkologie$$x4
000156721 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x5
000156721 9201_ $$0I:(DE-He78)M010-20160331$$kM010$$lM010 Stiftungsvorstand$$x6
000156721 9201_ $$0I:(DE-He78)DD01-20160331$$kDD01$$lDKTK DD zentral$$x7
000156721 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK MU LMU zentral$$x8
000156721 9201_ $$0I:(DE-He78)TU01-20160331$$kTU01$$lDKTK TU zentral$$x9
000156721 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK ED ES zentral$$x10
000156721 980__ $$ajournal
000156721 980__ $$aVDB
000156721 980__ $$aI:(DE-He78)BE01-20160331
000156721 980__ $$aI:(DE-He78)FR01-20160331
000156721 980__ $$aI:(DE-He78)HD01-20160331
000156721 980__ $$aI:(DE-He78)FM01-20160331
000156721 980__ $$aI:(DE-He78)E210-20160331
000156721 980__ $$aI:(DE-He78)E050-20160331
000156721 980__ $$aI:(DE-He78)M010-20160331
000156721 980__ $$aI:(DE-He78)DD01-20160331
000156721 980__ $$aI:(DE-He78)MU01-20160331
000156721 980__ $$aI:(DE-He78)TU01-20160331
000156721 980__ $$aI:(DE-He78)ED01-20160331
000156721 980__ $$aUNRESTRICTED